Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) frequently overexpresses the c-Met receptor, making it a key therapeutic target.
• Existing c-Met inhibitors have not yet achieved clinical success in treating hepatoma.
• Novel therapeutic strategies are needed to enhance the efficacy of c-Met inhibitors for HCC.

Purpose of the Study:

• To investigate the combined effects of dynasore, a dynamin inhibitor, with established c-Met inhibitors (tivantinib, PHA-665752, JNJ-38877605).
• To evaluate the potential of dynasore in potentiating the anti-cancer effects of c-Met inhibitors against hepatocellular carcinoma cells.

Main Methods:

• Hepatoma cell lines were treated with dynasore in combination with different c-Met inhibitors.
• Cell proliferation, migration, cell cycle arrest, and apoptosis were assessed.
• Western blotting was used to analyze c-Met levels and downstream signaling pathway phosphorylation (AKT, MEK).

Main Results:

• Dynasore significantly enhanced the inhibitory effects of c-Met inhibitors on hepatoma cell proliferation and migration.
• Combinatorial treatments led to increased cell cycle arrest and apoptosis.
• The combination therapy markedly reduced c-Met levels and disrupted downstream signaling, including phosphorylation of AKT and MEK.

Conclusions:

• Dynasore potentiates the efficacy of c-Met inhibitors against hepatocellular carcinoma cells.
• This combination strategy shows promise for developing novel therapeutic approaches targeting c-Met in HCC.
• Further research may lead to improved clinical management of hepatocellular carcinoma patients.